NasdaqGM:ATAIPharmaceuticals
Is AtaiBeckley (ATAI) Redefining Its Psychedelic Strategy With Standalone EMP-01 Anxiety Data?
In April 2026, AtaiBeckley Inc. reported expanded Phase 2a data showing its oral R-MDMA candidate EMP-01 produced clinically meaningful, statistically significant improvements in adults with Social Anxiety Disorder across multiple symptom scales, with no severe or serious adverse events and high patient retention.
A distinctive aspect of these results is that EMP-01 delivered robust benefits in fear, avoidance, and real-world social functioning without adjunctive psychotherapy, highlighting...